Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated th...

Full description

Saved in:
Bibliographic Details
Published in:Nature medicine Vol. 28; no. 2; pp. 401 - 409
Main Authors: Li, Jingxin, Hou, Lihua, Guo, Xiling, Jin, Pengfei, Wu, Shipo, Zhu, Jiahong, Pan, Hongxing, Wang, Xue, Song, Zhizhou, Wan, Jingxuan, Cui, Lunbiao, Li, Junqiang, Chen, Yin, Wang, Xuewen, Jin, Lairun, Liu, Jingxian, Shi, Fengjuan, Xu, Xiaoyu, Zhu, Tao, Chen, Wei, Zhu, Fengcai
Format: Journal Article
Language:English
Published: New York Nature Publishing Group US 01.02.2022
Nature Publishing Group
Subjects:
631/250/2152/2153/1291
631/250/590/1883
692/308/2779/109/1943
Adenoviridae - immunology
Adenoviruses
Adolescent
Adult
Adults
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Biomedical and Life Sciences
Biomedicine
Cancer Research
China
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
COVID-19 Vaccines - immunology
Female
Homology
Humans
Immunization
Immunization, Secondary
Immunogenicity
Immunogenicity, Vaccine - immunology
Immunoglobulin G - blood
Infectious Diseases
Injection Site Reaction - pathology
Male
Metabolic Diseases
Middle Aged
Molecular Medicine
Neurosciences
Neutralizing
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Side effects
T-Lymphocytes - immunology
Vaccination
Vaccines
Vaccines, Inactivated - immunology
Viral diseases
Young Adult
China
ISSN:1078-8956, 1546-170X, 1546-170X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial ( NCT04892459 ). Adults who had received two doses of CoronaVac in the past 3–6 months were vaccinated with Convidecia ( n  = 96) or CoronaVac ( n  = 102). Adults who had received one dose of CoronaVac in the past 1–3 months were also vaccinated with Convidecia ( n  = 51) or CoronaVac ( n  = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting. Heterologous vaccination with Convidecia, a recombinant adenovirus type 5-vectored COVID-19 vaccine, after one or two doses of CoronaVac, an inactivated SARS-CoV-2 vaccine, is more reactogenic but elicits significantly higher levels of neutralizing antibodies than homologous vaccination.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:1078-8956
1546-170X
1546-170X
DOI:10.1038/s41591-021-01677-z